Apollo Hospitals extends fall as drug mark-up concerns

Enterprise Limited (APOLLOHOSP) fell 2.3% to ₹7,978 in early trade on October 1, extending losses for a second session. The stock was among the top Nifty 50 losers, a day after closing 6.6% lower on Supreme Court remarks about medicine mark-ups at private hospitals. The court cited a cancer drug with an MRP of ₹27,000 despite a price to retailers of ₹2,700. It questioned whether a uniform 16% margin could apply to medicines, and raised concerns about hospitals making patients buy through in-house pharmacies. The selling was sector-wide. Max Healthcare, Fortis Healthcare and KIMS were also down over 2% today. The concern is real, but its size is still unclear. Jefferies estimates medicines and consumables make up around 15-20% of hospital revenue. It puts the potential EBITDA impact at 2-5% under various price-cap scenarios, assuming hospitals cannot pass it on. The brokerage kept its positive view on the sector. HSBC also flagged pricing intervention as a key concern, while noting the ground-level impact remains uncertain. Most importantly, this is not yet a rule. The court's observations have not turned into a binding price-control order. The two-day fall reflects the market pricing in regulatory risk before any policy exists. Investors should watch for any government or regulatory action on hospital medicine pricing, the next court hearing, and management commentary in Q2 FY27 results. The key question is whether this ends as court observations or becomes a formal margin cap on hospital pharmacies. Disclosure: I do not hold any position in Apollo Hospitals Enterprise Limited. This post is for informational purposes only and is not investment advice.